NT-proBNP

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is produced when the precursor hormone proBNP is cleaved into two fragments: the biologically active BNP, which acts on blood vessels and kidneys to promote vasodilation and natriuresis, and NT-proBNP, an inactive fragment that is cleared more slowly from the bloodstream. This slower clearance gives NT-proBNP a longer half-life (approximately 120 minutes compared to 20 minutes for BNP), making it a more stable and analytically reliable measurement target.

The stimulus for proBNP production is mechanical stretch of cardiomyocytes, which occurs when the heart is under pressure or volume overload. Conditions that increase cardiac filling pressures — such as systolic or diastolic heart failure, valvular disease, and pulmonary hypertension — cause measurably higher NT-proBNP concentrations. Normal reference ranges vary by age, sex, and body mass index, with higher thresholds applied for older adults and lower thresholds for obese patients, in whom natriuretic peptide levels may be paradoxically reduced.

NT-proBNP is measured through standardized immunoassay platforms and is incorporated into major heart failure guidelines as a diagnostic and prognostic tool. A single NT-proBNP value below established thresholds has high negative predictive value for ruling out heart failure in the acute setting, while serial measurements are used to guide treatment intensity and assess decompensation risk in chronic heart failure patients.

Prevena Health is exploring whether continuous NT-proBNP monitoring may provide earlier warning of hemodynamic deterioration in heart failure patients. Current practice relies on periodic blood draws during clinic visits or hospitalizations, creating gaps in longitudinal data during which significant changes in cardiac status may go undetected. Continuous surveillance aims to capture the kinetics of NT-proBNP change in real time, potentially alerting clinicians to decompensation trends before they progress to symptomatic episodes.

This approach may be particularly valuable for patients recently discharged after heart failure hospitalization, a period associated with high readmission rates. By tracking NT-proBNP trends through a wearable biosensor platform, Prevena aims to support clinicians in identifying patients who may benefit from earlier intervention, potentially reducing the burden of repeat hospitalizations and improving quality of life for heart failure patients.